Atria Investments Inc Cuts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Atria Investments Inc trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 12.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,869 shares of the medical research company's stock after selling 2,480 shares during the quarter. Atria Investments Inc's holdings in Charles River Laboratories International were worth $3,299,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Charles River Laboratories International in the 3rd quarter valued at about $601,000. JPMorgan Chase & Co. raised its stake in shares of Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after acquiring an additional 85,759 shares during the period. State Street Corp raised its stake in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after acquiring an additional 41,421 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock valued at $22,060,000 after acquiring an additional 3,714 shares during the period. Finally, Janus Henderson Group PLC raised its stake in shares of Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after acquiring an additional 3,268 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CRL shares. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. UBS Group reissued a "neutral" rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a research note on Monday, March 3rd. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Finally, William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $198.36.

Charles River Laboratories International Stock Up 4.1 %

NYSE CRL traded up $6.93 on Friday, hitting $176.20. 1,169,106 shares of the stock were exchanged, compared to its average volume of 699,906. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $274.77. The company has a market cap of $9.01 billion, a PE ratio of 1,174.68, a PEG ratio of 4.54 and a beta of 1.45. The company has a 50-day moving average price of $169.15 and a 200-day moving average price of $185.76.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same quarter in the prior year, the business posted $2.46 EPS. The company's revenue for the quarter was down 1.1% on a year-over-year basis. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Birgit Girshick purchased 1,514 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).